Estetrol and Drospirenone

Drug Overview

In the field of Gynecology, the combination of estetrol and drospirenone represents a significant advancement in the Combined Oral Contraceptive (COC) drug class. This medication is the first to utilize estetrol, a unique plant-derived estrogen that is identical to a hormone naturally produced by the human fetal liver during pregnancy. When paired with drospirenone, a well-established progestin, this Hormone Modulator offers a highly targeted approach to reproductive health with a distinct safety profile.

This contraceptive is designed for women who seek reliable pregnancy prevention while prioritizing a medication that has a selective impact on different body tissues, specifically aiming to minimize effects on the liver and breast tissue compared to traditional synthetic estrogens.

• Generic Name: Estetrol and Drospirenone
• US Brand Names: NEXTSTELLIS
• Drug Class: Combined Oral Contraceptive (COC)
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Approved in 2021 for the prevention of pregnancy.

What Is It and How Does It Work? (Mechanism of Action)

The combination of estetrol and drospirenone acts as a sophisticated Hormone Modulator that works primarily by suppressing the signal for ovulation. Its efficacy is rooted in its ability to manage the hypothalamic-pituitary-ovarian (HPO) axis at a molecular level.

HPO Axis Modulation

Estetrol and drospirenone provide negative feedback to the hypothalamus and pituitary gland. This suppressive action prevents the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). Without the mid-cycle surge of LH, the ovaries do not release an egg, effectively preventing the possibility of fertilization.

Tissue-Selective Estrogen Activity

Estetrol (E4) is a unique estrogen characterized as a Native Estrogen with Selective Action in Tissues (NEST). Unlike ethinyl estradiol found in most pills, estetrol acts as an agonist (activator) on estrogen receptors in the bones, vagina, and uterus to maintain health, but it shows antagonistic (blocking) or neutral activity in the liver and breast. This selectivity helps maintain a lower impact on liver-produced clotting factors.

Progestogenic Activity

Drospirenone serves as the progestin component. Beyond its role in HPO suppression, it causes:

• Cervical Mucus Thickening: Altering the consistency of mucus to make it impenetrable to sperm.
• Endometrial Alteration: Changing the lining of the uterus to make it unreceptive to implantation.
• Antimineralocorticoid Activity: Drospirenone is chemically similar to a natural diuretic, which helps reduce water retention and bloating, a common concern for women on hormonal birth control.

FDA-Approved Clinical Indications

Primary Gynecological/Obstetric Indications

• Pregnancy Prevention: Indicated for use by females of reproductive potential to prevent pregnancy.

Off-Label / Endocrinological Indications

• Acne Vulgaris: Due to the anti-androgenic properties of drospirenone, it may be used to manage hormonal acne.
• Premenstrual Dysphoric Disorder (PMDD): Management of severe physical and emotional symptoms before menstruation.
• Cycle Regulation: Stabilization of irregular menstrual cycles and reduction of heavy withdrawal bleeding.
• Polycystic Ovary Syndrome (PCOS): Management of androgen excess symptoms and ensuring regular endometrial shedding.

Dosage and Administration Protocols

To maintain maximum contraceptive efficacy, the medication must be taken daily at the same time in the order prescribed on the blister pack.

Administration Guidelines:

• Start Time: It is recommended to start on Day 1 of the menstrual cycle (Day 1 Start) or the first Sunday following the start of menstruation (Sunday Start).
• Missed Doses: If one active tablet is missed, take it as soon as remembered. If two or more are missed, follow the specific “missed pill” instructions in the patient insert and use backup contraception (e.g., condoms) for 7 days.
• Renal/Hepatic Insufficiency: Contraindicated in patients with renal impairment or hepatic impairment due to the risk of hyperkalemia (high potassium) associated with drospirenone and altered hormone metabolism.

Clinical Efficacy and Research Results

Clinical trials conducted between 2020 and 2026, including the pivotal Phase 3 E4Freedom studies, have provided precise numerical data regarding the efficacy of this estetrol-based combination.

• Contraceptive Efficacy: The Pearl Index (the number of unintended pregnancies per 100 woman-years) was calculated at 2.1 in the North American study and 0.47 in the European/Russian study. This demonstrates a high success rate in pregnancy prevention.
• Cycle Control: Approximately 97% of women in clinical trials experienced predictable scheduled bleeding or “withdrawal” bleeding during the placebo phase.
• Metabolic Impact: Numerical data showed minimal changes in liver binding proteins (SHBG) and lipid profiles. For instance, the increase in Sex Hormone Binding Globulin (SHBG) was significantly lower than that seen with ethinyl estradiol-based pills, suggesting a potentially lower risk of venous thromboembolism (VTE).
• Bleeding Patterns: Precise tracking showed a reduction in the number of bleeding and spotting days over time, moving from an average of 5.8 days in Cycle 1 to 4.5 days by Cycle 6.

Safety Profile and Side Effects

Black Box Warning

CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS: Cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Women who use combined oral contraceptives are strongly advised not to smoke.

Common Side Effects (>10%)

• Irregular bleeding (spotting or breakthrough bleeding), especially in the first few months.
• Headache or migraine.
• Breast tenderness or pain.
• Mood changes or irritability.
• Dysmenorrhea (painful periods).

Serious Adverse Events

• VTE/Thrombosis Risk: An increased risk of blood clots in the legs (DVT) or lungs (PE).
• Hyperkalemia: Drospirenone can increase potassium levels; caution is required in patients taking other potassium-sparing medications (e.g., ACE inhibitors).
• Hypertension: Possible increase in blood pressure.
• Gallbladder Disease: Slight increased risk of gallstones.

Management Strategies:

Side effects like spotting usually resolve after 3 cycles of consistent use. For mood changes or persistent headaches, a clinical review of the HPO axis response may be required. If hyperkalemia is suspected, serum potassium levels should be checked during the first cycle of treatment.

Research Areas

In current women’s health research (2024-2026), estetrol is being investigated for its potential in Endometrial Regeneration and as a component in Targeted Therapy for menopausal symptoms. Due to its fetal origins and selective tissue activity, scientists are exploring how this estrogen might be used in the future for “Vascular Sparing” hormone replacement. Currently, clinical trials are also evaluating the use of drospirenone in novel delivery systems, such as long-acting vaginal rings, to improve patient adherence.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Pregnancy Test: To confirm the patient is not pregnant before starting.
• Blood Pressure: Baseline measurement is mandatory.
• Potassium Levels: Specifically for patients on chronic medications for blood pressure or heart health.
• Pelvic Exam/Cervical Screening: As per age-appropriate standard gynecological care guidelines.

Precautions During Treatment:

• Symptom Vigilance: Patients must be educated on the “ACHES” acronym (Abdominal pain, Chest pain, Headaches, Eye problems, Severe leg pain) as indicators of potential blood clots.
• Contraceptive Requirements: Use a backup method if starting the pill late or if experiencing severe vomiting/diarrhea.
• Lifestyle: Smoking cessation is highly recommended for all users.

Do’s and Don’ts:

• DO take the pill at the same time every day to maintain steady hormone levels.
• DO check for drug interactions with medications like Rifampin or certain anti-seizure drugs.
• DON’T smoke if you are over the age of 35 and using this medication.
• DON’T skip inert (placebo) tablets as they help maintain the daily habit of pill-taking.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice from a qualified healthcare provider. Decisions regarding hormonal contraception should be made in consultation with a licensed Gynecologist or healthcare professional to ensure the medication is appropriate for your individual medical history.